Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cyclacel Pharmaceuticals, Inc. (CYCC : NSDQ)
 
 • Company Description   
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.38 Daily Weekly Monthly
20 Day Moving Average: 67,274 shares
Shares Outstanding: 9.99 (millions)
Market Capitalization: $13.79 (millions)
Beta: 1.39
52 Week High: $7.95
52 Week Low: $1.29
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.23% -22.51%
12 Week -58.81% -53.70%
Year To Date -64.52% -56.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 CONNELL DRIVE SUITE 1500
-
BERKELEY HEIGHTS,NJ 07922
USA
ph: 908-517-7330
fax: 866-271-3466
ir@cyclacel.com http://www.cyclacel.com
 
 • General Corporate Information   
Officers
Spiro Rombotis - Chief Executive Officer and President
Christopher Henney - Chairman
Robert Spiegel - Vice Chairman
Paul McBarron - Chief Operating Officer and Chief Financial Office
Samuel L. Barker - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23254L603
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 9.99
Most Recent Split Date: 4.00 (0.05:1)
Beta: 1.39
Market Capitalization: $13.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.15 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.41
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 16.00%
vs. Previous Quarter: 22.22%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -50.41
12/31/21 - -44.58
09/30/21 - -48.76
ROA
03/31/22 - -45.10
12/31/21 - -40.78
09/30/21 - -44.95
Current Ratio
03/31/22 - 5.90
12/31/21 - 7.73
09/30/21 - 12.08
Quick Ratio
03/31/22 - 5.90
12/31/21 - 7.73
09/30/21 - 12.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.34
12/31/21 - 3.73
09/30/21 - 4.48
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©